Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04611880 · ClinicalTrials.gov registry record · Phase 2
Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)
A Phase 2 study of RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT04611880 is a Phase 2 study of RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 20 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT04611880, a Phase 2 study of RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase 2 trial that will test the efficacy and safety of crizanlizumab for the treatment of retinal vasculopathy with cerebral leukoencephalopathy (RVCL), a very rare and uniformly fatal genetic condition that affects the microvasculature, especially of the brain and eye. There currently is no treatment for RVCL. A maximum of 20 patients will be enrolled.
Conditions Studied
Interventions
- DRUG Crizanlizumab
Study Locations (2)
Missouri
- Andria Ford - St Louis
Pennsylvania
- Perelman School of Medicine; University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-01-25 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04611880
The ClinicalTrials.gov registry entry for NCT04611880 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy appearing as the primary indexed condition, and to 1 intervention - of which Crizanlizumab is the first listed.
NCT04611880 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Missouri, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04611880 about?
NCT04611880 is a clinical study titled "Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)". This is a Phase 2 trial that will test the efficacy and safety of crizanlizumab for the treatment of retinal vasculopathy with cerebral leukoencephalopathy (RVCL), a very rare and uniformly fatal genetic condition that affects the microvasculature, especially of the brain and eye. There currently is...
What is the current status of trial NCT04611880?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2021-01-25. Estimated completion is 2025-12-31.
What conditions does trial NCT04611880 study?
This clinical trial studies the following conditions: RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy.
What interventions are being tested in trial NCT04611880?
The interventions under investigation include: Crizanlizumab (DRUG).
Who is sponsoring clinical trial NCT04611880?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04611880 being conducted?
This trial has 2 study locations across Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.